Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tal Zaks

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Nature Medicine|April 22, 2022
Author Correction: A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virusAllison August, Husain Z Attarwala, Sunny Himansu, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 3, 2022
Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza VirusesKapil Bahl, Joe J Senn, Olga Yuzhakov, et al.
Vaccine|May 14, 2019
mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trialsRobert A Feldman, Rainard Fuhr, Igor Smolenov, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 2, 2017
Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza VirusesKapil Bahl, Joe J Senn, Olga Yuzhakov, et al.
JAMA Oncology|May 28, 2021
Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for CancerAmir Massarweh, Noa Eliakim-Raz, Amos Stemmer, et al.
Cancer Research|October 8, 2009
Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinasesFawn Qian, Stefan Engst, Kyoko Yamaguchi, et al.
Human Vaccines & Immunotherapeutics|October 30, 2020
A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adultsAntonios O Aliprantis, Christine A Shaw, Paul Griffin, et al.
Cancer Cell|April 20, 2004
Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defectsDavid A Tuveson, Alice T Shaw, Nicholas A Willis, et al.
The Journal of Clinical Investigation|October 5, 2020
mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancerGal Cafri, Jared J Gartner, Tal Zaks, et al.
Nucleic Acid Therapeutics|January 4, 2024
Report of the European Medicines Agency Conference on RNA-Based MedicinesFalk Ehmann, Andreas Kuhn, Anna Maria Gerdina Pasmooij, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Nature Medicine|April 22, 2022
Author Correction: A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virusAllison August, Husain Z Attarwala, Sunny Himansu, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 3, 2022
Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza VirusesKapil Bahl, Joe J Senn, Olga Yuzhakov, et al.
Vaccine|May 14, 2019
mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trialsRobert A Feldman, Rainard Fuhr, Igor Smolenov, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 2, 2017
Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza VirusesKapil Bahl, Joe J Senn, Olga Yuzhakov, et al.
JAMA Oncology|May 28, 2021
Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for CancerAmir Massarweh, Noa Eliakim-Raz, Amos Stemmer, et al.
Cancer Research|October 8, 2009
Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinasesFawn Qian, Stefan Engst, Kyoko Yamaguchi, et al.
Human Vaccines & Immunotherapeutics|October 30, 2020
A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adultsAntonios O Aliprantis, Christine A Shaw, Paul Griffin, et al.
Cancer Cell|April 20, 2004
Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defectsDavid A Tuveson, Alice T Shaw, Nicholas A Willis, et al.
The Journal of Clinical Investigation|October 5, 2020
mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancerGal Cafri, Jared J Gartner, Tal Zaks, et al.
Nucleic Acid Therapeutics|January 4, 2024
Report of the European Medicines Agency Conference on RNA-Based MedicinesFalk Ehmann, Andreas Kuhn, Anna Maria Gerdina Pasmooij, et al.
Pageof 3